I'm LongbridgeAI, I can summarize articles.Hangzhou Tigermed Consulting Co., Ltd. has announced a buyback plan for its A shares, aiming to repurchase between RMB500 million and RMB1 billion at a maximum price of RMB60 per share. The buyback will cover approximately 8.33 million to 16.67 million shares, representing 0.97% to 1.94% of total share capital, over a period of up to 12 months. The repurchased shares will be allocated to an equity incentive scheme and for cancellation to reduce registered capital. This move is expected to enhance shareholder value and align employee interests.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has shared an update.
Hangzhou Tigermed Consulting has unveiled a plan to repurchase between RMB500 million and RMB1 billion of its publicly held A shares through centralized price bidding, at a maximum price of RMB60 per share. The repurchased stock will be partly allocated to an A share equity incentive scheme or employee stock ownership plan and partly cancelled to reduce the company’s registered capital, with no more than 60% used for incentives and at least 40% earmarked for cancellation.
Based on the price cap, the buyback would cover an estimated 8.33 million to 16.67 million shares, representing about 0.97% to 1.94% of total share capital, over a period of up to 12 months following general meeting approval. Management and major shareholders currently have no definite plans to reduce their holdings in the next six months, and the move is expected to support capital management, align employee interests, and potentially enhance shareholder value, subject to regulatory and policy adjustments.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization (CRO) serving the pharmaceutical and biotech industries. The company provides clinical trial, consulting and related R&D services, with its shares listed in both A share and H share markets, giving it access to domestic and international investors focused on healthcare innovation.
Average Trading Volume: 1,634,388
Technical Sentiment Signal: Sell
Current Market Cap: HK$44.48B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.